IRVINE, CA, and HERSTAL, BELGIUM – January 10, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that it will release its financial results for the full year ended 31 December 2019 on Wednesday 26 February 2020.
Michael K. McGarrity, Chief Executive Officer and Ron Kalfus, Chief Financial Officer, will host a conference call and Q&A session at 09:00am CET on the day of the announcement. The call will be conducted in English and a replay will be available for 30 days. Conference coordinates to be posted by early February.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
|Consilium Strategic Communications (IR & PR)
Amber Fennell, Chris Welsh, Marieke Vermeersch, Nicholas Brown
UK: +44 20 3709 5701
TE: The MDxHealth logo, MDxHealth, ConfirmMDx, and SelectMDx are trademarks or registered trademarks of MDxHealth SA.